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Introduction: The ability of doublet therapy in the second-line
setting in patients with platinum-refractory non-small cell lung
cancer (NSCLC) has not yet been proven. In this setting, docetaxel
(D) has shown efficacy and irinotecan (I) has only recently been
introduced. This study was initiated to explore the activity and tolera-
bility of three D  I regimens in platinum pretreated NSCLC patients.
Methods: From March 2003 to June 2006, 65 patients (age range,
39–71 years; 83% male) with relapsed stage III/IV NSCLC were
randomly assigned to receive either I 160 mg/m2 plus D 60 mg/m2
on day 1 every 21 days (arm A), I 80 mg/m2 on days 1,8 plus D 60
mg/m2 on day 1 every 21 days (arm B), or I 60 mg/m2 plus D 30
mg/m2 on days 1, 8, 15, and 22 every 42 days (arm C), for a
maximum of 18 weeks.
Results: Per protocol analysis (47 of 65) overall response rates were
5.6% (A), 6.7% (B), and 7.1% (C). Median times to progression
were 3.4, 4.0, and 4.3 months, respectively. Overall survival was 8.9
(A), 8.3 (B), and 9.4 (C) months. G3/4 neutropenia was more
frequent in arms A (42%) and B (55%) whereas G3/4 nonhemato-
logic toxicity was similarly prevalent in all arms, although diarrhea
occurred in 47% of arm C patients.
Conclusions: Single-agent treatment with D or the multitarget
antifolate pemetrexed or erlotinib remain the best choices and
investigational studies, following first-line therapy, are required.
Key Words: Docetaxel, Irinotecan, Second-line chemotherapy,
Non-small cell lung cancer, Phase II, Randomized trial.
(J Thorac Oncol. 2008;3: 405–411)
Approximately 30% of patients with non-small cell lungcancer (NSCLC) have locally advanced disease at diag-
nosis; 45% of these patients have metastases; after receiving
first-line chemotherapy, patients have a 40 to 50% likelihood
of survival at 1 year.1 A considerable proportion of patients
with disease progression after first-line treatment has good
performance status and may benefit from second-line treat-
ment. However, until the year 2000, in the absence of active
second-line chemotherapy, best supportive care or investiga-
tional trials were the only options available to these patients.
At that time, based on two phase III randomized trials,2,3 do-
cetaxel became the standard second-line treatment for NSCLC.4
Notwithstanding a low response rate, trials based on treatment
with docetaxel reported an improvement in survival and quality
of life, compared with best supportive care2 and to ifosfamide or
vinorelbine.3 However, at the standard dose (75 mg/m2 every 21
days), docetaxel is associated with a significant rate of hemato-
logic toxicity and neutropenic fever.5
In a phase III study,6 the multitarget antifolate agent
pemetrexed demonstrated clinically equivalent therapeutic out-
comes but a more favorable hematologic toxicity profile com-
pared with docetaxel. Pemetrexed has thus been proposed as the
best available single agent for treating NSCLC in the second-
line setting, even though response rate is less than 10%.6
More recently erlotinib, an inhibitor of tyrosine kinase
epidermal growth factor receptor, has demonstrated superiority
in terms of overall survival and time to progression compared
with best supportive care in pretreated patients with NSCLC.7
To date, docetaxel, pemetrexed, and erlotinib are considered
equivalent options in a nonselected second-line setting.
Irinotecan, a topoisomerase I inhibitor, has shown prom-
ising activity as first-line treatment in advanced NSCLC, both as
a single agent8–10 and in combination with platinum com-
pounds.11–13 In preclinical studies, irinotecan has demon-
strated a broad spectrum of antitumor activity.14–16 The
maximum tolerated dose of irinotecan given as a single agent
was determined in phase I studies, where late diarrhea and
neutropenia were dose-limiting toxicities. Phase II studies of
irinotecan as a single agent for NSCLC reported response
rates of 15 to 34% and median survival times of 6 to 10
months. Toxicities resulting from the recommended dosage
of irinotecan (350 mg/m2 given every 3 weeks as a 30- to
90-minute infusion) included diarrhea (any grade) in 87% of
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patients, grade 3/4 neutropenia in 45%, fatigue in 20%, and
nausea and vomiting in 20%.16
Preclinical studies of irinotecan in combination with
taxanes revealed additive or synergistic effects17 that may be
schedule-dependent. Moreover, a phase I study showed that
irinotecan can be safely administered in combination with
docetaxel,18 and a 3-week schedule of administration of
irinotecan (160 mg/m2) plus docetaxel (65 mg/m2) was rec-
ommended for further phase II investigation. Other studies
indicated feasibility with weekly schedules or dosing on days
1 and 8 every 21 days.19–21
Based on these results, we undertook a phase II, ran-
domized, three-arm study to explore the activity and tolera-
bility of three different irinotecan-docetaxel regimens as
second-line therapy in patients with NSCLC. We also sought
to determine a schedule of administration that would produce
optimal activity and toxicity profiles. Our decision to study a
combination therapy is based on evidence that irinotecan and
docetaxel differ from platinum compounds in their mechanisms
of action and resistance, apparently do not have overlapping
toxicity, and produce potentially synergistic activity that may
amplify the response rate obtained with single-agent therapy.
METHODS
Study Population
Patients meeting all the following criteria were enrolled:
cytologically proven recurrent or metastatic NSCLC after pre-
vious first line chemotherapy course containing cisplatin or
carboplatin, at least 1 measurable lesion according to Response
Evaluation Criteria in Solid Tumors (RECIST),22 interval of
more than 4 weeks from the last chemotherapy application, with
all toxic effects completely resolved. Patients with only previous
adjuvant chemotherapy were not allowed. Additional inclusion
criteria were a performance status of 0 to 1 according to the
Eastern Cooperative Oncology Group scale,23 life expectancy
12 weeks, and adequate bone marrow reserve (neutrophil
count 2000/l, platelet count 100,000/l, and hemoglo-
bin 10 g/dl), as well as adequate kidney, liver, and cardiac
function. Previous radiotherapy was allowed only if the
extent of bone marrow involvement was 10%, treatment
stopped at least 4 weeks before study entry, and assessable
disease was outside the radiation field.
Patients with a history or presence of brain or menin-
geal metastases, prior malignancy, contraindications to use of
atropine sulfate, peripheral neuropathy more than grade 2
according to National Cancer Institute Common Toxicity
Criteria criteria,24 or serious systemic disorder were excluded
from the study. Women of childbearing potential were re-
quired to use an approved form of contraception over the
study period.
Written informed consent was obtained from all pa-
tients before inclusion. The study protocol was approved by
the Ethics Committees of all participating centers.
Study Design
This is a prospective, three-arm, randomized, multi-
center, phase II trial. Patients were first stratified according to
response obtained with front-line chemotherapy, i.e., as re-
sponsive (previous complete or partial response) or unrespon-
sive (previous stabilization or progressive disease), and by
participating center.
Patients were randomly assigned to receive irinotecan
160 mg/m2 intravenously (IV) and docetaxel at 60 mg/m2 IV
on day 1 every 21 days (arm A); irinotecan 80 mg/m2 on days
1 and 8 and docetaxel 60 mg/m2 on day 1, repeated every 21
days (arm B); or irinotecan 60 mg/m2 and docetaxel 30
mg/m2 on days 1, 8, 15, and 22 every 6 weeks (arm C). All
treatments were administered as a 60-minute infusion in 250
ml normal saline, except in arm C, where docetaxel 30 mg/m2
was administered over 30 minutes.
Patients received ondansetron 8 mg and dexamethasone
8 mg, intravenously, and atropine sulfate 0.25 mg subcuta-
neously, as premedication for irinotecan infusion. Patients in
arms A and B also received oral methylprednisolone 16 mg
the evening before docetaxel infusion, 48 mg the day of
infusion, and 32 mg the day after infusion. In arm C, patients
received oral methylprednisolone 16 mg the day before and
32 mg the day of docetaxel infusion.
Most chemotherapy infusions were administered on an
outpatient basis. Treatment was considered complete after six
cycles in arms A and B and after three cycles in arm C, for a
total of 18 weeks of treatment in each arm. Patients could be
withdrawn from the study if disease progression, unaccept-
able toxicity, withdrawal of consent, physician decision, or
need for palliative external beam radiotherapy occurred.
Toxicity was graded according to National Cancer Insti-
tute Common Toxicity Criteria criteria24 and assessed on day 1
in arm A, on days 1 and 8 in arm B, and weekly in arm C by
means of physical examination, direct questions, and measure-
ment of hematologic and biochemical variables. If neutrophil
count was 1500/l or platelet count was 100,000/l, a
1-week delay was required in arm A; in arm B day 8 and in arm
C weekly infusion were omitted. In addition to the delay, for
grade 4 neutropenia or thrombocytopenia, or febrile neutro-
penia, docetaxel and irinotecan doses were stepped down as
follows: irinotecan, to 130 mg/m2 (arm A), 65 mg/m2 (arm
B), or 50 mg/m2 (arm C); docetaxel, to 50 mg/m2 (arms A
and B) or 25 mg/m2 (arm C). Chemotherapy was stopped 2
weeks after the previous cycle if neutrophil counts had not
recovered. If further episodes of grade 4 neutropenia or
thrombocytopenia occurred after dose reduction, chemother-
apy was stopped. Irinotecan and docetaxel doses were also
reduced for grade 3/4 diarrhea. Patients with diarrhea were
immediately prescribed oral loperamide. For diarrhea persist-
ing for more than 48 hours, prophylactic oral fluoroquinolone
was given, and patients were hospitalized for rehydration.
The docetaxel dose was also reduced for grade 3 mucositis or
grade 2/3 neurologic toxicity.
Use of granulocyte-colony stimulating factor (G-CSF)
was not allowed during treatment except in patients with
febrile neutropenia or grade-4 neutropenia according to
American Society of Clinical Oncology guidelines.25 Sup-
portive treatments, including blood transfusion, erythropoie-
tin, antibiotics, antiemetics, and analgesics, were adminis-
tered when considered appropriate by the investigators.
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Medical history was taken and physical examination
performed 1 week before randomization (baseline), before
each infusion, and at the end of treatment. Electrocardiogra-
phy was performed within 14 days before randomization.
Hematologic and biochemical analyses were performed 7
days before randomization and repeated before each cycle.
Complete blood counts were furthermore monitored weekly
while patients were on study. Brain, chest, and upper abdo-
men computed tomography, and bone scan were performed at
least 28 days before randomization. Computed tomography
was performed every 6 weeks thereafter to assess tumor
response according to RECIST.22 Duration of response was
determined from the date of randomization until disease
progression. Post treatment response evaluation were per-
formed every 2 months for at least 12 months or until death.
Data Analysis
Primary study endpoints were efficacy, as determined
by objective response rate (complete plus partial response)
according to RECIST,22 and safety, as determined by severe
toxicity (grade 3/4 according to the NCIC-CTC criteria).24
Secondary endpoints were time to progression, time to treat-
ment failure, and survival time (see below for definition).
All endpoints were assessed in patients in arm A and B
completing at least two cycles of chemotherapy, or at least
one cycle in arm C, in patients without protocol violation
(evaluable population) and in all randomly assigned patients.
Statistical Methodology
Sample size estimation was done according to the
Briant & Day approach,26 by assessing each treatment inde-
pendently. This approach is an extension of the two-stage
design proposed by Simon,27 in that it jointly considers both
efficacy and tolerability. To have adequate power to assess
treatment efficacy, 21 patients were required to be accrued
into each arm at the first stage. Treatment arms with less than
three objective responses or with excessive toxicity (defined
as containing fewer than 14 patients free of grade 3/4 toxic-
ity) were considered inadequate for evaluation of activity.
The second step required 46 patients per arm, for a total of
138 patients. In the second step, treatment arms with fewer
than eight responses or with excessive toxicity (defined as
fewer than 32 patients free of grade 3/4 toxicity) were also
considered inadequate for evaluation of activity.
Input parameters used to determine sample size origi-
nated from probability of accepting poor response r 0.10,
probability of accepting toxic treatment t0.10, probability
of rejecting good treatment  0.10, unacceptable response
probability pr0  0.10, acceptable response probability pr1 
TABLE 1. Demographic and Clinical Characteristics of the Study Population at Time of Randomization (n  65)
Arm A
(n  24)
Arm B
(n  22)
Arm C
(n  19)
Age (yr, mean  SD, range) 58.3  8.1 (39–70) 58.7  8.0 (40–68) 60.7  7.3 (42–71)
Male (n, %) 21 (87.5) 17 (77.3) 12 (84.2)
Weight (kg, mean  SD) 75.1  13.7 73.6  12.1 68.9  8.1
Height (cm, mean  SD) 170.4  5.5 168.0  11.6 165.5  7.2
Concomitant diseases (n, %) 14 (58.3) 9 (40.9) 11 (57.9)
Concomitant drug treatments (n, %) 24 (100.0) 22 (100.0) 19 (100.0)
ECOG performance status (n, %)
0 13 (54.2) 12 (54.5) 9 (47.4)
1 11 (45.8) 10 (45.5) 10 (52.6)
Histologic type (n, %)
Adenocarcinoma 18 (75.0) 13 (59.1) 10 (52.6)
Squamous-cell carcinoma 5 (20.8) 8 (36.4) 7 (36.9)
Others 1 (4.2) 1 (4.5) 2 (10.5)
Extent of disease (n, %)
Stage IV 17 (70.8) 17 (77.3) 11 (57.9)
Other 7 (29.2) 5 (22.7) 8 (42.1)
No. of disease sites (n, %)
2 15 (62.5) 10 (45.5) 9 (47.4)
2 9 (37.5) 12 (54.5) 10 (52.6)
Previous first-line chemotherapy (n, %)
Cisplatin or carboplatin or oxaliplatin  gemcitabine 19 (79.2) 15 (68.2) 12 (63.2)
Cisplatin  vinorelbine 2 (8.3) 4 (18.2) 4 (21.1)
Others 3 (12.5) 3 (13.6) 3 (15.7)
Previous response to chemotherapy (n, %) 13 (54.2) 9 (40.9) 11 (57.9)
Previous surgery for neoplasia (n, %) 6 (25.0) 10 (45.5) 8 (42.1)
Previous radiotherapy (n, %) 5 (20.8) 7 (31.8) 8 (42.1)
ECOG, Eastern Cooperative Oncology Group.
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0.30, unacceptable toxicity probability pt0  0.40, and ac-
ceptable toxicity probability pt1  0.20.
Proportions of patients with objective response or un-
acceptable toxicity were estimated with corresponding 95%
confidence intervals. Survival for each treatment, calculated
from date of randomization to date of death or most recent
follow-up examination, was represented using Kaplan-Meier
curves. The same approach was employed for describing time
to progression (measured from randomized treatment assign-
ment to the first date of documented progression or death) and
time to treatment failure (measured from date of initial
treatment to documented progression, withdrawal from study
treatment, administration of other antitumor therapy, or death
for any cause).
RESULTS
Patient and Treatment Characteristics
Sixty-five patients (24 in arm A, 22 in Arm B, 19 in arm
C; age range, 39–71 years; 83% male) were enrolled between
March 2003 and June 2006. Baseline patient characteristics
are summarized in Table 1. All patients had received first-line
platinum-based chemotherapy and were well balanced for
previous response and number of metastatic sites, with 51%
previously responding to treatment and 52% having two or
fewer disease sites. Patients had a performance status of 0
(52%) or 1 (48%). The most common histologic NSCLC type
was adenocarcinoma (63%); 69% of patients had stage IV
disease at study entry. All patients were taking concomitant
medications at time of randomization, and concomitant dis-
eases (mainly diabetes, dyslipidemia, and hypertension) were
present in 52% of patients.
Response, Survival, and Time to Progression
Forty-seven of the 65 randomized patients were evalu-
able for efficacy: 7 patients were excluded from analysis
because of protocol violations, 3 did not have postbaseline
assessments, and 8 did not complete the minimum period of
treatment. Response analysis results are summarized in Table
2. No complete responses were observed. In the evaluable
population, 1 patient in arm A (5.6%; 95% confidence inter-
val (CI), 0.1% to 27.3%), 1 in arm B (6.7; 95% CI, 0.2% to
31.9%), and 1 in arm C (7.1%; 95 CI, 0.2% to 33.9%) had a
partial remission. Overall 6.5% of patients responded to
treatment. Disease was stable in 13 (72.2%), 8 (53.3%), and
10 (71.5%) patients in arms A, B, and C, respectively;
progression occurred in 4 (22.2%), 6 (40.0%), and 3 (21.4%)
patients.
Because of statistical methods and sample size deter-
mination criteria, the minimum number of objective re-
sponses required (at least three per arm) to designate the
combination as active was not achieved. Consequently en-
rollment was discontinued, and the study was stopped after
reaching the first-stage sample size of 21 patients.
Median time to progression was 3.4 months (95% CI,
2.8–4.8) in arm A, 4.0 months (95% CI, 1.7–8.0) in arm B,
and 4.3 months (95% CI, 2.2–7.5) in arm C (Figure 1);
median time to treatment failure was 2.8 months (95% CI,
1.5–3.6), 4.0 months (95% CI, 1.5–7.9), and 2.6 months (95%
CI, 1.7–4.4). Overall survival was 8.9 months (95% CI,
6.0–12.3) for arm A, 8.3 months (95% CI, 5.9–12.9) for arm
B, and 9.4 months (95% CI, 6.5–13.4) for arm C (Figure 2).
For the 31 patients with stable disease, 27 (87.1%) had
received previous platinum-based first-line chemotherapy, of
whom 15 (55.6%) had a documented response. Previous
response did not influence the probability of a response to
FIGURE 1. Kaplan-Meier curves for time to progression for
the evaluable population (n  47). Data are shown for arms
A (continuous line, n  18), B (dashed line, n  15), and C
(dotted line, n  14). Results of the log-rank test are also
reported.
FIGURE 2. Kaplan-Meier survival curves for the evaluable
population (n  47). Data are shown for arms A (continuous
line, n  18), (dashed line, n  15) and C (dotted line, n  14).
Results of the log-rank test are also reported.
TABLE 2. Objective Response Rate to Treatment in Patients
Evaluable for Efficacy (n  47)
Arm A
(n  18)
n (%)
Arm B
(n  15)
n (%)
Arm C
(n  14)
n (%)
Complete remission –– –– ––
Partial remission 1 (5.6) 1 (6.7) 1 (7.1)
Stable disease 13 (72.2) 8 (53.3) 10 (71.5)
Progressive disease 4 (22.2) 6 (40.0) 3 (21.4)
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second-line chemotherapy in any arm. The results for all
randomly assigned patients were similar to those for evalu-
able patients (Table 3).
Toxicity
In all randomly assigned patients, rates of grade 3/4
toxicity occurred in 14 patients in arm A (58.3%; 95% CI,
36.6–77.9%), 14 in arm B (63.6%; 95% CI, 40.7–82.8%),
and 12 in arm C (63.2%; 95% CI, 38.4–83.7%).
With regard to hematologic toxicity, grade 3/4 neutrope-
nia was the most common, occurring in 38.5% of patients
(particularly in arms A and B), followed by grade 3/4 leukopenia
(9.2%) and anemia (3.1%) (Table 4). Grade 1/2 hematologic
toxicities were less common than grade 3/4 hematologic toxic-
ities (Table 5).
Grade 3/4 diarrhea was the most common nonhemato-
logic drug-related adverse event, occurring in 18 patients
(27.7%), mainly in arm C. Nausea or vomiting was reported
by 37 patients (56.9%), but only 6 patients (9.2%) experi-
enced it at grade 3/4. Other common drug related adverse
events were fatigue, fever, and alopecia (Tables 4 and 5).
Grade 3 alopecia was rare, occurring in 2 patients (3.1%);
grade 1/2 alopecia was more frequent (27.7%), with greater
incidence in patients in arm A.
One death occurred in arm C due to treatment-related
toxicity (diarrhea with dehydration, followed by hypotension
and hypovolemic shock).
DISCUSSION
Platinum-based doublet regimens administered in the
first line improved overall survival and quality of life in
patients with advanced NSCLC. Many trials have been con-
ducted to assess the efficacy of second-line chemotherapy; to
date, only monotherapy with docetaxel2–4 or pemetrexed,6
and more recently with erlotinib,7 has improved survival in
these patients.
Since 2000, docetaxel became the treatment paradigm
in which only best supportive care was recommended for
patients who relapsed after first-line platinum-based chemo-
therapy. In the study by Shepherd et al.,2 patients receiving
docetaxel, demonstrated improved overall survival at 1 year
compared with best supportive care (37% versus 11%, re-
spectively). However, docetaxel administered at a dosage of
100 mg/m2 was associated to significant toxicity and five
deaths related to adverse events occurred. A dosage of 75
mg/m2 was therefore recommended for clinical use. In a
second phase III trial, Fossella et al.3 compared patients
receiving docetaxel (75 mg/m2 or 100 mg/m2) with those in
the control arm, receiving vinorelbine or ifosfamide. The
response rate observed with docetaxel, even though limited,
was superior (6.7% and 10.8% for the two dose regimens
respectively) to the one obtained in the control arm (0.8%). In
addition, as shown in a previous phase III trial,28 a 1-year
survival rate of 32% observed in patients receiving docetaxel
reached statistical significance, with an improvement of 10%
over that of patients receiving vinorelbine or ifosfamide.
Results from previous trials of single-agent chemother-
apy prompted us to design this phase II study with three
different schedules of docetaxel administration in combina-
TABLE 3. Efficacy Results in Randomized Patients (n  65)
Arm A
(n  24)
n (%) (95% CI)
Arm B
(n  22)
n (%) (95% CI)
Arm C
(n  19)
n (%) (95% CI)
Complete remission  partial remission 1 (4.2) (0.1–21.1) 1 (4.5) (0.1–22.8) 1 (5.3) (0.1–26.0)
Stable disease 18 (75.0) 10 (45.5) 10 (52.6)
Median (95% CI) Median (95% CI) Median (95% CI)
Time to progression (mo) 3.8 (2.8–6.5) 3.5 (1.7–7.1) 3.5 (1.9–6.3)
Time to treatment failure (mo) 2.6 (1.6–3.3) 2.6 (1.5–7.0) 2.2 (1.1–3.0)
Survival (mo) 8.9 (6.8–NC) 8.3 (6.0–12.2) 9.6 (6.5–13.4)
CI  confidence interval; NC  Non-Computable.
TABLE 4. Grade 3/4 Toxicity in Randomized Patients (n  65)
Arm A
(n  24)
n
Arm B
(n  22)
n
Arm C
(n  19)
n
Total
(n  65)
n (%)
Neutropenia 10 12 3 25 (38.5)
Leukopenia 2 3 1 6 (9.2)
Anemia 2 0 0 2 (3.1)
Diarrhea 4 5 9 18 (27.7)
Nausea or vomiting 5 0 1 6 (9.2)
Fatigue 3 0 3 6 (9.2)
Fever 2 1 1 4 (6.2)
Alopecia 0 1 1 2 (3.1)
TABLE 5. Grade 1/2 Toxicity in Randomized Patients (n  65)
Arm A
(n  24)
n
Arm B
(n  22)
n
Arm C
(n  19)
n
Total
(n  65)
n (%)
Neutropenia 0 2 2 4 (6.2)
Leukopenia 1 0 0 1 (1.5)
Anemia 2 0 1 3 (4.6)
Diarrhea 10 8 7 25 (38.5)
Nausea or vomiting 12 5 14 31 (47.7)
Asthenia or fatigue 1 6 3 10 (15.4)
Fever 2 3 3 8 (12.3)
Alopecia 10 6 2 18 (27.7)
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tion with irinotecan, a new agent in the second-line treatment
of NSCLC that has shown promising results in monotherapy
or combination therapy for patients with advanced disease as
first-line chemotherapy.11–13 Although a number of phase I
trials explored the use of docetaxel combined with irinote-
can,20,21,29,30 their varying schedules, sequences of infusion,
and toxicity profiles did not produce a clear indication of the
optimal combination regimen to employ in clinical practice.
Moreover, the safety and efficacy of this combination in
various schedules has not been so far investigated in a phase
II study.
This is the first randomized trial exploring the activity
and safety of three dosages and schedules of irinotecan and
docetaxel used as combination therapy in second-line setting
in patients with advanced NSCLC. In all three treatment
arms, when provided as scheduled, patients received infu-
sional docetaxel followed by infusional irinotecan. In patients
in whom irinotecan was administered before docetaxel, ac-
tivity of the cytochrome P450 3A4 system may have been
induced, thereby lessening the exposure to docetaxel. How-
ever, previous studies conducted to explore this effect did not
show an increase in docetaxel clearance, and clinical phar-
macokinetic activity was maintained.29,30 With regard to
efficacy, docetaxel combined with irinotecan produced a very
low response rate in our study: only three partial remissions
were confirmed overall in the population evaluable for effi-
cacy (6.5%). Stable disease was observed in 65% of the entire
patient population, with a median time to progression of 3 to
4 months and a median survival time of 8 to 9 months.
Although time to progression tended to be higher for patients
in arm B (irinotecan 80 mg/m2 on day 1 and 8 plus docetaxel
60 mg/m2 on day 1, every 21 weeks), no statistical conclu-
sions can be made as this trial was not powered to observe a
significant statistical differences between the treatment arms.
Overall toxicity was moderate in all treatment arms. As
in other trials, diarrhea frequently occurred after treatment
with docetaxel and irinotecan31–33 and, in the majority of
patients, was resolved after treatment with high-dose loper-
amide. Nevertheless, the incidence of severe diarrhea (grade
3/4) tended to be higher in arm C (47.4% versus 19.6% in the
other 2 arms combined). Indeed, one patient died in arm C
due to grade 4 diarrhea and dehydration complicated by
electrolyte alterations and consequent fatal dysrhythmia. Among
hematologic toxicities, neutropenia occurred most frequently;
arm C showed a lower incidence of neutropenia (15.8%)
compared with the other two arms (41.7% in arm A and
54.5% in arm B). A slightly higher incidence of anemia was
seen in arm A. In conclusion weekly administration of irino-
tecan and docetaxel (arm C) seemed to be better tolerated as
hematological toxicities respect to gastrointestinal adverse
events; these findings reflect the tolerability profile showed
by single agent administration with a possible worsening due
to doublet therapy.
Despite the inability to complete a comparison for
efficacy due to trial premature closure, however, it is inter-
esting to note that time to progression in our study is similar
to the one obtained in other phase II studies31,32 and compa-
rable to results obtained in large phase III trials exploring
second-line chemotherapy in advanced NSCLC.2–7 Neverthe-
less, compared with recently published studies involving both
first- and second-line chemotherapy applying the same regi-
mens, our study had lower overall activity (as determined by
best response) and, in arm C, a higher number of episodes of
severe diarrhea.
There are no plausible explanations for this lack of
activity, although another phase II study32 demonstrated a
similar (10%) response rate with the combination of do-
cetaxel 60 mg/m2 and irinotecan 200 mg/m2 on day 1 every
21 days plus G-CSF administered prophylactically from day
2 to day 12. Recently, two other phase II trials explored the
activity and safety of this combination,34,35 with results sim-
ilar to those of previous studies. In one study, 40 patients
received irinotecan 160 mg/m2 followed by docetaxel 65 mg/m2
on day 1 every 21 days; an overall response rate of 10% was
observed. The most common grade 3/4 adverse events were
neutropenia (62%), neutropenic fever (22%), and diarrhea
(32%). In a second study, 35 patients received irinotecan 50
mg/m2 plus docetaxel 33 mg/m2 bi-weekly and achieved a
response rate of 14%, with grade 3/4 neutropenia observed in
54% of patients. In another phase II trial, docetaxel 80 mg/m2
and irinotecan 200 mg/m2 (administered on day 1 every 21
days) plus G-CSF administered prophylactically from day 2
to 9 was employed in the first-line setting.36 In this study, the
objective response rate was 23%, with a median survival time
of 10.8 months and 1-year-survival rate of 42.2%. The activ-
ity of this regimen suggests that this nonplatinum-based
chemotherapy is relatively active as first-line treatment and
could be administered to patients with contraindications to
cisplatin. It is also probable that the objective response rate
and the clinical benefit are related more to dosing of irinote-
can and docetaxel than to different sequences of infusion. The
use of prophylactic G-CSF is probably important in the
improved safety of this combination even if it is difficult to
enhance the activity especially when this combination is
administered in second-line setting in which NSCLC shows
an intrinsic resistance to chemotherapy.
The combination of docetaxel and irinotecan produced
predictable and generally manageable toxicities. However,
patients in arm C demonstrated an unacceptable incidence
of grade 3/4 diarrhea, likely related to the dose intensity of
both drugs.
Even if the results are similar compared with literature,
the originality of our study was a rigorous attempt to better
understand if the activity of the combination was influenced
by different schedule using an infusion sequence between
docetaxel and irinotecan driven by previous pharmacokinet-
ics knowledge.
In conclusion, in our study, the combination docetaxel
plus irinotecan in pretreated patients with NSCLC demon-
strated a lack of activity and a toxicity profile less favorable
than has been observed in previous phase II and III trials
using docetaxel alone. Even if time to progression and overall
survival with this combination were similar to that observed
with other second-line regimens, docetaxel or pemetrexed
monochemotherapy and erlotinib remain the standard second-
line treatments in platinum refractory patients. Therefore,
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studies of regimens combining drugs with newer mechanisms
of action are warranted in platinum-refractory, advanced
NSCLC patients.
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